Acquired RD3 loss regulates immune surveillance in high-risk and therapy defying progressive neuroblastoma

Poorvi Subramanian; Sreenidhi Mohanvelu; Dinesh Babu Somasundaram; Sheeja Aravindan; Natarajan Aravindan

doi:10.1002/cac2.12620

Cancer Communications ›› 2024, Vol. 44 ›› Issue (12) : 1427 -1430. DOI: 10.1002/cac2.12620

LETTER TO THE JOURNAL

Acquired RD3 loss regulates immune surveillance in high-risk and therapy defying progressive neuroblastoma

Author information +

History +

PDF

Cite this article

Download citation ▾

Poorvi Subramanian, Sreenidhi Mohanvelu, Dinesh Babu Somasundaram, Sheeja Aravindan, Natarajan Aravindan. Acquired RD3 loss regulates immune surveillance in high-risk and therapy defying progressive neuroblastoma. Cancer Communications, 2024, 44(12): 1427-1430 DOI:10.1002/cac2.12620

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Verhoeven BM, Mei S, Olsen TK, Gustafsson K, Valind A, Lindstrom A, et al. The immune cell atlas of human neuroblastoma. Cell Rep Med. 2022; 3(6): 100657.

[2]	Vanichapol T, Chutipongtanate S, Anurathapan U, Hongeng S. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma. Biomed Res Int. 2018; 2018: 1812535.

[3]	Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, et al. Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol. 2022; 13: 844142.

[4]	Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012; 23 Suppl (8): viii6-9.

[5]	Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20): 1267-84.

[6]	Aravindan S, Somasundaram DB, Kam KL, Subramanian K, Yu Z, Herman TS, et al. Retinal Degeneration Protein 3 (RD3) in normal human tissues: Novel insights. Sci Rep. 2017; 7(1): 13154.

[7]	Aravindan N, Somasundaram DB, Aravindan S, Yu Z, Karthikeyan S, Herman TS. Heterogeneous distribution of retinal degeneration protein 3 in human fetal normal tissues. J Interdiscip Histopathol 2019; 7(2): 106.

[8]	Khan FH, Pandian V, Ramraj SK, Aravindan S, Natarajan M, Azadi S, et al. RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes. Oncotarget. 2015; 6(34): 36522-34.

[9]	Somasundaram DB, Subramanian K, Aravindan S, Yu Z, Natarajan M, Herman T, Aravindan N. De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution. Sci Rep. 2019; 9(1): 11766.

[10]	Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7): 773-82.